平肺口服液在非小细胞肺癌放疗中的应用

Effects of Pingfei oral liquid in the radiotherapy of patients with non-small-cell lung carcinoma

目的:观察平肺口服液对行胸部放疗的非小细胞肺癌患者放射性肺炎和肺纤维化发生率的影响,以及血清中转化生长因子-β1(TGF-β1)水平的变化。方法:将符合入组条件的98例非小细胞肺癌患者随机分为观察组50例和对照组48例。两组均接受常规胸部放射治疗,其中观察组在放疗同时予平肺口服液口服3个疗程,对照组进行单纯放疗。结果:对照组放射性肺炎(≥2级)发生率为33.3%,观察组为22.0%(P<0.05);放疗结束后6个月对照组放射性肺纤维化发生率42%,观察组18%(P<0.05);观察组放疗结束时及结束后2周的血清TGF-β1均显著低于对照组(P<0.01)。结论:平肺口服液可以减少放射性肺炎及肺纤维化的发生率,并降低血清TGF-β1水平,对放射性肺损伤具有一定预防作用。

Objective：To evaluate the effects of Pingfei oral liquid （PFOL）in radiation pneumopathy protection and serum transforming growth factor-β1 （TGF-β1）level changes due to thoracic radiotherapy in non-smallcell lung carcinoma（NSCLC）patients.Methods ：Ninty-eight NSCLC patients were randomized into two groups：the observed group （50 cases）and control group （48 eases）.Both groups received routine thoracic radiotherapy,and PFOL oral administration was also given to the observed group for three courses of treatment.Results：The incidence of radiation pneumonia（≥Grade 2）was 33.3% in the control group,and 22.0% in the observed group （P〈0.05）.The incidence of pulmonary fibrosis six months after radiotherapy was 42% in the control group, and 18% in observed group（P〈0.05）.In addition,serum TGF-β1 levels in observed group were lower than that of the control group both at the end of thoracic radiotherapy and two weeks after irradiation（P〈0.01 ）.Conclusion：PFOL could reduce the incidence of radiation pneumonia,pulmonary fibrosis and serum TGF-β1 increase due to thoracic radiotherapy.PFOL was able to prevent radiation pneumopathy in some extent.